HomeREGULATORY
REGULATORY

Chuikyo Discussing Measures to Promote Proper Use of Clozaril for Patients with Treatment-Resistant Schizophrenia
(Oct.19.2017)

Chuikyo General Meeting on Oct. 18
The Central Social Insurance Medical Council, a health ministry reimbursement panel better known as Chuikyo, has begun discussing a plan to promote the proper use of Novartis Pharma’s Clozaril (clozapine), a treatment for treatment-resistant schizophrenia ...
(LOG IN FOR FULL STORY)

News Calendar